Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novartis readies for...

    Novartis readies for FDA review of 1 billion dollar CAR-T child cancer hope

    Written by Ruby Khatun Khatun Published On 2017-07-14T09:20:37+05:30  |  Updated On 14 July 2017 9:20 AM IST

    ZURICH: Two decades ago in a Memphis, Tenn., hospital lab, cancer scientist Dario Campana and his team were hunting for a new way to fight deadly acute lymphoblastic leukemia (ALL).


    They began with several molecules, but finally settled on one, called 4-1BB, because it seemed to prime the human immune system to attack blood cancer more aggressively than others.


    "Our first tests convinced us these T cells were special," Campana, now a scientist at the National University Cancer Institute in Singapore, told Reuters by email this week.


    "I had never seen any drug killing leukemic cells so rapidly and specifically."


    Come Wednesday, it will be showtime for his molecule, when the U.S. Food and Drug Administration publicly reviews Novartis' investigational drug, CTL019, for safety and effectiveness against ALL in children.


    Campana's 4-1BB is the key ingredient of the Swiss drugmaker's therapy, which involves T cells being extracted from patients, genetically re-engineered, and then unleashed to kill leukemia cells growing out of control.


    Of 68 desperately ill children who started Novartis's pediatric ALL trial 17 months ago when other treatments had failed, 57 are alive. Novartis' chief drug developer Vas Narasimhan thinks Campana's molecule is a big reason why.


    "This might be part of the reason we see the profile that we do in terms of long-lasting remissions with CTL019," he said.


    The chimeric antigen receptor therapy developed by Novartis, called CAR-T, is poised to become the first of its kind to secure FDA approval, ahead of Kite Pharma and Juno Therapeutics.


    The Swiss drugmaker eventually expects more than $1 billion in annual sales, including from the treatment of other forms of cancer in adults.



    Paternity Dispute


    The discovery of 4-1BB by Campana, an Italian, and his Japanese colleague Chihaya Imai, during their tenure at St. Jude's Children's Research Hospital in Memphis, had gone relatively unheralded.


    Instead, the University of Pennsylvania, including its cancer immunotherapy pioneer Carl June that borrowed the molecule from Campana in the early 2000s for his own work, has won most of the accolades.


    Around the time Novartis struck a multi-million deal with Penn to commercialize CTL019 in 2012, St. Jude's sued the university, alleging patent violations.


    Moreover, Campana's and Imai's names were left off the Penn team's publications.


    But the patent dispute was finally settled in 2015, when Novartis agreed to pay $12.25 million, plus royalties.


    The scientific record has been set straight too. Last year, June's team updated three New England Journal of Medicine publications that had previously ignored Campana's contribution.


    Despite the initial snub, Campana is rooting for Novartis' drug.


    "Many scientists have contributed in different ways to the development of this technology," said Campana, a founder of Boston-based cancer immunotherapy company Unum Therapeutics.


    "It is wonderful that it works."




    (Reporting by John Miller; Editing by Alexander Smith)



    4-1BBacute lymphoblastic leukemiablood cancercancer scientistCAR-Tchild cancerCTL019Dario CampanaFDAhopehuman immune systeminvestigational drugleukemiamoleculesNational University Cancer InstituteNovartisSingaporeT cellsU.S. Food and Drug AdministrationVas Narasimhan
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok